Menopause Review (Dec 2010)
Wpływ zastosowanych gestagenów w ciągłej hormonalnej terapii zastępczej na wydzielanie insulinotropowego peptydu zależnego od glukozy i peptydu glukanopodobnego 1 u kobiet po menopauzie
Abstract
Aim of the study: To evaluate GIP and GLP-1 secretion in postmenopausal women on the HRT in relation togestagen used. Material and method: 105 postmenopausal women (mean age 59.0 ±3.4 years) were included in the study.Group I (n = 32) consisted of women treated with oral dydrogesterone and transdermal 17-b- estradiol. Group II(n = 30) was treated with 17-b-estradiol and dydrogesterone orally. Group III (n = 15) received 17-b-estradioltransdermally and medroxyprogesterone orally. Women from group IV (n = 10) received 17-b-estradiol and noretisteroneorally. Blood was taken twice – before and 60 min. after the meal - to the chilled tubes with EDTA andaprotinin. Such a protocol was used before the HRT began and in the 6th month of the HRT. Results: The HRT resulted in diminished plasma concentration of GIP and GLP-1 in both group I and II – beforeand after the meal (p < 0.05). In group III the same tendency in GIP levels was observed but the differenceswere not statistically significant. The GLP-1 concentrations were not affected by HRT, as well as GIP and GLP-1levels in group IV. Conclusion: The plasma concentration of incretins (GIP and GLP-1) depends on the route of HRT delivery andon the kind of gestagen used.
